Universitat de Lleida
    • English
    • català
    • español
  • English 
    • English
    • català
    • español
  • Login
Repositori Obert UdL
View Item 
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias

Thumbnail
View/Open
025786.pdf (2.198Mb)
Issue date
2017-04-28
Author
Dosil Garcia, Maria Alba
Mirantes Barbeito, Cristina
Eritja Sánchez, Núria
Felip, Isidre
Navaridas Fernández de Bobadilla, Raúl
Gatius Calderó, Sònia
Santacana Espasa, Maria
Colás, Eva
Moiola, Cristian P.
Schoenenberger, Joan Antoni
Encinas Martín, Mario
Garí Marsol, Eloi
Matias-Guiu, Xavier
Dolcet Roca, Xavier
Suggested citation
Dosil Garcia, Maria Alba; Mirantes Barbeito, Cristina; Eritja Sánchez, Núria; Felip, Isidre; Navaridas Fernández de Bobadilla, Raúl; Gatius Calderó, Sònia; ... Dolcet Roca, Xavier. (2017) . Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias. Journal of Pathology, 2017, vol. 242, núm. 2, p. 152-164. https://doi.org/10.1002/path.4896.
Impact


Web of Science logo    citations in Web of Science

Scopus logo    citations in Scopus

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
PTEN is one of the most frequently mutated genes in human cancers. The frequency of PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to dysregulation of cell division, and promotes the accumulation of cell cycle complexes such as cyclin D1-CDK4/6, which is an important feature of the tumour phenotype. Cell cycle proteins have been presented as key targets in the treatment of the pathogenesis of cancer, and several CDK inhibitors have been developed as a strategy to generate new anticancer drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole. Here, we used a tamoxifen-inducible Pten knockout mouse model to assess the antitumour effects of cyclin D1 knockout and CDK4/6 inhibition by palbociclib on endometrial tumours. Interestingly, both cyclin D1 deficiency and palbociclib treatment triggered shrinkage of endometrial neoplasias. In addition, palbociclib treatment significantly increased the survival of Pten-deficient mice, and, as expected, had a general effect in reducing tumour cell proliferation. To further analyse the effects of palbociclib on endometrial carcinoma, we established subcutaneous tumours with human endometrial cancer cell lines and primary endometrial cancer xenografts, which allowed us to provide more translational and predictive data. To date, this is the first preclinical study evaluating the response to CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, and it reveals an important role of cyclin D-CDK4/6 activity in their development.
URI
http://hdl.handle.net/10459.1/63495
DOI
https://doi.org/10.1002/path.4896
Is part of
Journal of Pathology, 2017, vol. 242, núm. 2, p. 152-164
European research projects
Collections
  • Articles publicats (Medicina Experimental) [323]
  • Articles publicats (Ciències Mèdiques Bàsiques) [548]
  • Articles publicats (IRBLleida) [1054]
  • Publicacions de projectes de recerca del Plan Nacional [2626]

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to 
 

 

Browse

All of the repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

View Usage Statistics

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contact Us | Send Feedback | Legal Notice
© 2022 BiD. Universitat de Lleida
Metadata subjected to